441 related articles for article (PubMed ID: 36210836)
1. Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: A pan-cancer analysis.
Yang L; Zhang Y; Wang Y; Jiang P; Liu F; Feng N
Front Pharmacol; 2022; 13():938134. PubMed ID: 36210836
[TBL] [Abstract][Full Text] [Related]
2. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
[TBL] [Abstract][Full Text] [Related]
3. Multi-omics pan-cancer study of cuproptosis core gene
Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
Front Immunol; 2022; 13():981764. PubMed ID: 36605188
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the functional effects of ferredoxin 1 as a cuproptosis biomarker in cancer.
Li X; Dai Z; Liu J; Sun Z; Li N; Jiao G; Cao H
Front Genet; 2022; 13():969856. PubMed ID: 36226187
[No Abstract] [Full Text] [Related]
5. A Novel Cuproptosis-Related Prognostic Model and the Hub Gene
Zhang K; Yang W; Zhang Z; Ma K; Li L; Xu Y; Qiu J; Yu C; Zhou J; Cai L; Gong Y; Gong K
J Oncol; 2022; 2022():2124088. PubMed ID: 36536785
[TBL] [Abstract][Full Text] [Related]
6. Pancancer analysis of the correlations of HS6ST2 with prognosis, tumor immunity, and drug resistance.
Chen W; Li X; Jiang Y; Ni D; Yang L; Wu J; Gao M; Wang J; Song J; Shi W
Sci Rep; 2023 Nov; 13(1):19209. PubMed ID: 37932473
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and immunological role of cuproptosis-related protein FDX1 in pan-cancer.
Xiao C; Yang L; Jin L; Lin W; Zhang F; Huang S; Huang Z
Front Genet; 2022; 13():962028. PubMed ID: 36061184
[No Abstract] [Full Text] [Related]
8. Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker.
Zhang C; Zeng Y; Guo X; Shen H; Zhang J; Wang K; Ji M; Huang S
Front Genet; 2022; 13():923737. PubMed ID: 35991547
[No Abstract] [Full Text] [Related]
9. Cuproptosis-related gene
Wang T; Liu Y; Li Q; Luo Y; Liu D; Li B
Front Immunol; 2022; 13():999823. PubMed ID: 36225932
[TBL] [Abstract][Full Text] [Related]
10. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and immunological role of FDX1 in pan-cancer: an in-silico analysis.
Liu Z; Miao J
Sci Rep; 2023 May; 13(1):7926. PubMed ID: 37193786
[TBL] [Abstract][Full Text] [Related]
12. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
13. Systematic pan-cancer analysis identifies cuproptosis-related gene DLAT as an immunological and prognostic biomarker.
Xu L; Wu P; Rong A; Li K; Xiao X; Zhang Y; Wu H
Aging (Albany NY); 2023 May; 15(10):4269-4287. PubMed ID: 37199628
[TBL] [Abstract][Full Text] [Related]
14. Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma.
Lu H; Zhou L; Zhang B; Xie Y; Yang H; Wang Z
Front Med (Lausanne); 2022; 9():939776. PubMed ID: 36523779
[TBL] [Abstract][Full Text] [Related]
15. Tumor cuproptosis and immune infiltration improve survival of patients with hepatocellular carcinoma with a high expression of ferredoxin 1.
Quan Y; Li W; Yan R; Cheng J; Xu H; Chen L
Front Oncol; 2023; 13():1168769. PubMed ID: 37361595
[TBL] [Abstract][Full Text] [Related]
16. A cuproptosis-related gene signature and associated regulatory axis in stomach adenocarcinoma based on bioinformatics analysis.
Ding D; Wang D; Qin Y
Medicine (Baltimore); 2023 Jul; 102(30):e34230. PubMed ID: 37505170
[TBL] [Abstract][Full Text] [Related]
17. High expression of cuproptosis-related gene FDX1 in relation to good prognosis and immune cells infiltration in colon adenocarcinoma (COAD).
Wang L; Cao Y; Guo W; Xu J
J Cancer Res Clin Oncol; 2023 Jan; 149(1):15-24. PubMed ID: 36173462
[TBL] [Abstract][Full Text] [Related]
18. A pan-cancer analysis of DDR1 in prognostic signature and tumor immunity, drug resistance.
Yang L; Zhang Y; Tang Y; Wang Y; Jiang P; Liu F; Feng N
Sci Rep; 2023 Apr; 13(1):5779. PubMed ID: 37031216
[TBL] [Abstract][Full Text] [Related]
19. Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma.
Dai L; Zhou P; Lyu L; Jiang S
BMC Cancer; 2023 Dec; 23(1):1249. PubMed ID: 38114959
[TBL] [Abstract][Full Text] [Related]
20. A Novel Oncogenic Role of FDX1 in Human Melanoma Related to PD-L1 Immune Checkpoint.
Lu H; Liang J; He X; Ye H; Ruan C; Shao H; Zhang R; Li Y
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]